Multiple Myeloma | Specialty

ODAC Votes Against Panobinostat in Multiple Myeloma

November 6th 2014

In what was described as a very difficult decision, ODAC voted 5-2 against the accelerated approval of the HDAC inhibitor panobinostat in combination with bortezomib and dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy.

Three Specialists Offer Outlook on Employing Pomalidomide in Multiple Myeloma

November 4th 2014

As therapy options for patients with relapsed or refractory multiple myeloma have expanded in recent years, so have clinical considerations about how best to incorporate new agents into the treatment paradigm.

Dr. Jakubowiak Discusses the Future of Multiple Myeloma Treatment

October 17th 2014

Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the current and future state of multiple myeloma treatmen

Shifting the Paradigm?: Where Is Chemotherapy-and Particularly, High-Dose Therapy-Going in the Era of Biologic Agents?

October 15th 2014

The changes seen in multiple myeloma are a perfect illustration of a potentially shifting paradigm in cancer care.

FDA Schedules ODAC Hearing for Panobinostat in Multiple Myeloma

October 9th 2014

The FDA has scheduled an ODAC advisory hearing to discuss the new drug application for panobinostat in combination with bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Kyle's Keen Observations Led to a Lifetime of Discoveries in Plasma Disorders

September 19th 2014

Myeloma survivors owe much to Robert A. Kyle's reluctance to perform autopsies or to undergo cardiac catheterization.

Weekly Carfilzomib Safe and Effective in Relapsed or Refractory Multiple Myeloma

August 15th 2014

Administering carfilzomib once weekly in combination with dexamethasone is safe, with few ≥3 adverse events, and has significant antitumor activity in the treatment of patients with relapsed or refractory multiple myeloma.

Carfilzomib Monotherapy Misses Survival Endpoint in Heavily Pretreated Myeloma

August 14th 2014

Treatment with single-agent carfilzomib (Kyprolis) was unable to significantly extend overall survival (OS) compared with best supportive care in heavily pretreated patients with multiple myeloma

Daratumumab Active in Relapsed/Refractory Multiple Myeloma

August 14th 2014

Daratumumab, a fully human IgG1k monoclonal antibody that targets CD38, has demonstrated promising activity as monotherapy in patients with relapsed/refractory multiple myeloma

FDA Expands Bortezomib Multiple Myeloma Label

August 11th 2014

The FDA has expanded the bortezomib (Velcade) label to allow for retreatment in patients with multiple myeloma who previously responded to the proteasome inhibitor, according to an announcement made by Millennium/Takeda, the companies that manufacture the drug.

Carfilzomib Combination Effective for Relapsed Myeloma

August 4th 2014

The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and low-dose dexamethasone extended progression-free survival (PFS) by 8.7 months compared with lenalidomide and dexamethasone alone for patients with relapsed multiple myeloma

Emerging Agents for Multiple Myeloma

July 10th 2014

Management of Adverse Events in Multiple Myeloma

July 10th 2014

Maintenance Therapy for Patients With Multiple Myeloma

July 10th 2014

Pomalidomide and Carfilzomib in Multiple Myeloma

July 10th 2014

Pomalidomide in Refractory Multiple Myeloma

July 10th 2014

Treatment Decisions in Relapsed/Refractory Myeloma

July 10th 2014

Treatment Options in Newly Diagnosed Multiple Myeloma

July 10th 2014

High-Risk and Smoldering Multiple Myeloma

July 10th 2014

Imaging and Treatment Advances in Multiple Myeloma

July 10th 2014